Transforming greyscale

Transforming greyscale

into

into

information

information

.

.

Nextrast is developing novel CT contrast agents to vastly improve imaging capabilities through unprecedented spatial detail and 'color' CT functionality.

Nextrast is developing novel CT contrast agents to vastly improve imaging capabilities through unprecedented spatial detail and 'color' CT functionality.

Clinical Proof of Concept

Nextrast NX9

Dark Oral Contrast Agent

Nextrast NX9

Dark Oral Contrast Agent

Specifically designed to darken the bowel lumen, creating a high-contrast environment that makes vascularized tissues and tumors pop.

KEY BENEFITS

➜ Superior Anatomic Delineation
➜ Reduced Radiation Dose
➜ Improved Signal/Noise for AI

APPLICATIONS

  • Oncology Staging

  • Inflammatory Bowel Disease

  • MR Enterography

Clearly distinguishable anatomy

Conventional Positive

Oral Contrast

Similar shades of grey

IND Ready

Nextrast NX10

Novel Intravascular Agent

Nextrast NX10

Novel Intravascular Agent

A non-iodinated 'blood-pool' agent that remains in the vascular system for minutes, enabling unprecedented interrogation of blood vessels and the liver.

KEY BENEFITS

+ Extended Imaging Window
+ No Mixing Artifacts
+ High BMI Patient Solution

APPLICATIONS

  • Cardiovascular Disease

  • Trauma Triage

  • Liver Lesion Characterization

Vivid, prolonged, full-vascular enhancement

Non-Contrast

Non-
Contrast

6 sec

6s

40 sec

40s

75 sec

75s

136 sec

136s

240 sec

240s

Conventional Iodine
Poor and inconsistent opacification with rapid washout

Benjamin Yeh, MD

Founder

Brian Miller

CEO

Laura King

Board Member

Benjamin Yeh, MD

Founder

Brian Miller

CEO

Laura King

Board Member

Benjamin Yeh, MD

Founder

Brian Miller

CEO

Laura King

Board Member

The Leadership Team

With over 40 years experience, our team is focused on developing the next generation of medical imaging.

With over 40 years experience, our team is focused on developing the next generation of medical imaging.

All information proprietary & confidential

Nextrast Inc ©2026